Extended-release formulations of an injectable naltrexone and oral bupropion were associated with significant decreases in methamphetamine use, a new study showed.
Investigators leading the randomized clinical trial found a 27% increase in negative methamphetamine urine tests in the treatment group — indicating reduced use — compared with an 11% increase in negative urine tests in control participants.
A previous open-label study of NTX + BUPN showed efficacy for treating severe methamphetamine use disorder, and NTX and BUPN have each shown efficacy separately for this indication. The treatment group received extended-release NTX or placebo as an intramuscular injection on weeks 1, 4, 7 and 10. Extended-release BUPN or placebo tablets were administered weekly, with BUPN doses starting at 150 mg on day 1 and increasing to 450 mg by day 3. At week 13, participants received a tapering dose for 4 days before discontinuing., the two-drug combo was effective at reducing methamphetamine use at 6 weeks.
It"remains to be determined"whether continued use of NTX + BUPN treatment past 12 weeks would yield further reductions in use," the authors wrote, noting that prioruse disorder trials suggest that change in use is gradual and that sustained abstinence is unlikely in merely 12 weeks of a trial. Rather, it is dependent on treatment duration.
Methamphetamine Methamphetamine Use Toxicology Toxicity Poisoning Toxins Clinical Research Clinical Trials Clinical Studies Pre-Clinical Trial Double-Blind Study Double-Blind Studies Single-Blind Study Single-Blind Studies Healthcare And Medical Technology Health And Medical Tech Health And Med Tech Health And Medical Technology Healthcare Technology Medical Technology
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
A Festive Florida Wedding With Two Cocktail Hours, Two Aisles, Two Rabbis, and Two Receptions“Being a queer couple and J being trans-masculine non-binary, there was no ‘bride’ or ‘groom’ at the wedding, so we didn’t want our ceremony to have any gendered traditions,” the couple tells Vogue.
Read more »
New Drug Combo Boosts PFS in Hodgkin LymphomaA revised BEACOPP treatment has shown to improve progression-free survival in adults with advanced Hodgkin lymphoma, a large trial showed.
Read more »
New study demonstrates the efficacy of a promising celiac disease drug at the molecular levelA recent study investigated whether a transglutaminase 2 inhibitor has potential as a drug to treat celiac disease. Previous tissue studies have shown that the ZED1227 transglutaminase 2 inhibitor prevents gluten-induced intestinal damage.
Read more »
Promising drug target for treating osteoporosisOsteoporosis or the weakening of bones makes the aging population vulnerable to fractures and a decreased quality of life. The parathyroid hormone (PTH)-derived peptide -- teriparatide has demonstrated strong bone promoting effects. However, it is also to known to exert bone-resorbing effects.
Read more »
Healthy Returns: Drugmakers release promising cancer drug data – and AstraZeneca wins bigDrugmakers released cancer data at ASCO, with AstraZeneca taking center stage. A report found that digital physical therapy tools provide clinical benefits.
Read more »
Healthy Returns: Drugmakers release promising cancer drug data – and AstraZeneca wins bigDrugmakers released cancer data at ASCO, with AstraZeneca taking center stage. A report found that digital physical therapy tools provide clinical benefits.
Read more »